NewYork-Presbyterian has adopted Signal 1's AI Management System to govern every AI tool across the hospital network under one oversight platform, reflecting a shift from vetting individual AI products to managing a growing portfolio of predictive, generative, and agentic AI tools.
NHS England South East is rolling out Skin Analytics' DERM AI tool across all 18 regional hospital trusts, its largest autonomous-AI deployment to date, reaching about nine million more people. The system can discharge patients with benign lesions without a specialist visit, but regulators have kept its NHS approval conditional while more evidence is gathered.
A study in NEJM AI from Boston Children's Hospital's Manton Center and OpenAI found that the o3 model helped identify 18 new diagnoses among 376 previously unsolved rare-disease cases, including a 15-years-overdue diagnosis for one patient, while researchers caution the tool requires careful human oversight.
Insilico Medicine's rentosertib, an AI-designed drug for pulmonary fibrosis, entered Phase 3 trials on July 7, and the company's ISM6331 won FDA Fast Track designation for mesothelioma three weeks later — real progress in a field where no AI-discovered drug has yet won full approval.
DermaSensor's handheld AI skin-lesion scanner has won a European CE mark and launched an NHS feasibility study aimed at letting general practitioners, not just dermatologists, triage suspicious moles on the spot.
Labcorp is deploying PathAI's FDA-cleared AISight Dx platform across its national pathology network, a seven-year partnership reaching commercial scale even as independent data on real-world turnaround and accuracy gains remains limited.
A Chinese University of Hong Kong trial is testing whether adding an AI chatbot to an app-based insomnia therapy program for 18-to-25-year-olds improves adherence and sleep outcomes, standing in contrast to a wave of consumer sleep apps selling similar AI features without any published trial data.
GoGuardian's Beacon software now scans what students type into ChatGPT, Gemini, and other AI chatbots for signs of self-harm, and the company says it's flagged thousands of at-risk students — but reporting shows the system both over-alerts and misses real warnings, and GoGuardian won't release failure-rate data.
Harrison.ai won FDA clearance for an AI that triages stroke on the very first brain scan patients receive, rather than the follow-up angiogram most stroke-AI tools rely on, with sensitivity above 85% in its submission data.
Flok Health, a Cambridge-based company running what it calls Europe's first autonomous AI physiotherapy clinic for NHS patients, raised a $12.5 million Series A in June 2026 after a Cambridgeshire pilot cut a back-pain waiting list by 55 percent — a model that has also drawn pushback from physiotherapists over unsupervised discharge decisions.